AstraZeneca (LON:AZN) Reaches New 1-Year High – Here’s What Happened

Posted by Alanna Baker on Dec 19th, 2025

AstraZeneca PLC (LON:AZN – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Friday . The company traded as high as £154.74 and last traded at £135.85, with a volume of 422522813 shares traded. The stock had previously closed at £135.48.

Wall Street Analyst Weigh In

AZN has been the topic of several recent research reports. Jefferies Financial Group restated a “buy” rating and set a £150 target price on shares of AstraZeneca in a report on Monday, November 10th. JPMorgan Chase & Co. reissued an “overweight” rating and issued a £140 price objective on shares of AstraZeneca in a research note on Thursday, December 4th. Shore Capital restated a “buy” rating and issued a £145 target price on shares of AstraZeneca in a report on Thursday, November 6th. Finally, Berenberg Bank increased their price target on AstraZeneca from £142 to £145 and gave the company a “buy” rating in a report on Tuesday, October 21st. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of £138.

Read Our Latest Report on AstraZeneca

AstraZeneca Price Performance

The stock has a market capitalization of £211.95 billion, a P/E ratio of 22.71, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The company’s 50-day simple moving average is £132.02 and its 200-day simple moving average is £118.84.

AstraZeneca Company Profile

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.